Answers are grounded in this paper and cite their sources.
Neurologists often re‐test MOG‐IgG, but the frequency and factors associated with serostatus change are unknown. We examined this issue in a clinical cohort of patients serially tested for MOG‐IgG at Cleveland Clinic between 2017 and 2025. Kaplan–Meier curves estimated seroconversion/seroreversion‐free probability. Of 272 with serial testing, 16 seroreverted (to negative), 4 seroconverted (to positive). At 1 year, seroreversion‐free probability was 85% (95% CI: 76%, 96%) and seroconversion‐free probability was 98% (95% CI: 95%, 100%). Seroreversion occurred in 16 of 59 (27%), of whom 11 had titers < 1:100; none had further relapses. Seroconversion was uncommon (< 2%) and occurred in patients with steroid treatment at initial testing.
No takes yet. Share an insight, caveat, or question.
Havard‐Coiro et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: